Next Article in Journal
Metabolic Response to XD14 Treatment in Human Breast Cancer Cell Line MCF-7
Next Article in Special Issue
Melatonin: A Mitochondrial Targeting Molecule Involving Mitochondrial Protection and Dynamics
Previous Article in Journal
Trans-Stilbenes in Commercial Grape Juices: Quantification Using HPLC Approaches

Melatonin as a Potential Agent in the Treatment of Sarcopenia

Department of Morphology and Cellular Biology, Medicine Faculty, University of Oviedo, Julian Claveria, s/n, Oviedo 33006, Spain
Department of Cellular and Structural Biology, UTHSCSA, San Antonio, TX 78229, USA
Service of Microbiology, Hospital Universitario Central de Asturias, Avenida de Roma, s/n, Oviedo 33011, Spain
Author to whom correspondence should be addressed.
Academic Editor: Charles J. Malemud
Int. J. Mol. Sci. 2016, 17(10), 1771;
Received: 15 September 2016 / Revised: 17 October 2016 / Accepted: 17 October 2016 / Published: 24 October 2016
(This article belongs to the Special Issue Melatonin and Its Analogues: Experimental and Clinical Aspects)
Considering the increased speed at which the world population is aging, sarcopenia could become an epidemic in this century. This condition currently has no means of prevention or treatment. Melatonin is a highly effective and ubiquitously acting antioxidant and free radical scavenger that is normally produced in all organisms. This molecule has been implicated in a huge number of biological processes, from anticonvulsant properties in children to protective effects on the lung in chronic obstructive pulmonary disease. In this review, we summarize the data which suggest that melatonin may be beneficial in attenuating, reducing or preventing each of the symptoms that characterize sarcopenia. The findings are not limited to sarcopenia, but also apply to osteoporosis-related sarcopenia and to age-related neuromuscular junction dysfunction. Since melatonin has a high safety profile and is drastically reduced in advanced age, its potential utility in the treatment of sarcopenic patients and related dysfunctions should be considered. View Full-Text
Keywords: melatonin; sarcopenia; frailty; skeletal muscle; aging melatonin; sarcopenia; frailty; skeletal muscle; aging
Show Figures

Figure 1

MDPI and ACS Style

Coto-Montes, A.; Boga, J.A.; Tan, D.X.; Reiter, R.J. Melatonin as a Potential Agent in the Treatment of Sarcopenia. Int. J. Mol. Sci. 2016, 17, 1771.

AMA Style

Coto-Montes A, Boga JA, Tan DX, Reiter RJ. Melatonin as a Potential Agent in the Treatment of Sarcopenia. International Journal of Molecular Sciences. 2016; 17(10):1771.

Chicago/Turabian Style

Coto-Montes, Ana, Jose A. Boga, Dun X. Tan, and Russel J. Reiter 2016. "Melatonin as a Potential Agent in the Treatment of Sarcopenia" International Journal of Molecular Sciences 17, no. 10: 1771.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop